Emalex Biosciences

Focus: Emalex Biosciences is a Chicago-based biotechnology company focused on developing treatments for Tourette Syndrome and rare neurological disorders through its lead asset, Ecopipam. The company operates as a clinical-stage biotech with a diversified pipeline across multiple indications.

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Open Jobs

About Emalex Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Emalex Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ecopipam HCl ~2mg/kg/day

Tourettes Disorder

N/A

Clinical Trials (1)

NCT07093541Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder

N/A

Help build intelligence for Emalex Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Three Phase 3 programs (Tourette Syndrome, Lesch-Nyhan Disease, Tourette Disorder) represent near-term clinical catalysts and potential value inflection points
Focused pipeline on neuropsychiatric and rare diseases addresses significant unmet medical needs with limited competitive alternatives
Platform molecule (Ecopipam) with broad therapeutic potential across 6+ distinct indications demonstrates versatility and multiple shots on goal

Watch Out For

Zero current job openings and no disclosed funding data suggest minimal near-term hiring and potential capital constraints for scaling operations
Pre-revenue status with no financial disclosure creates significant uncertainty around runway, burn rate, and long-term sustainability

Generated by Claude from Emalex Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ecopipam HCl ~2mg/kg/day

Drug-Interactions

Phase 1

Clinical Trials (1)

NCT04764851Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Phase 1

[14C]-Ecopipam

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT04881955Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects

Phase 1

Ecopipam

Drug Interaction

Phase 1

Clinical Trials (1)

NCT05334108Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

Phase 1

Ecopipam Hydrochloride

QT/QTc

Phase 1

Clinical Trials (1)

NCT05841160Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

Phase 1

Ecopipam immediate release form

Healthy

Phase 1

Clinical Trials (1)

NCT01408394Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam

Phase 1

Itraconazole

Drug Interaction

Phase 1

Clinical Trials (1)

NCT06194864Drug Interaction Study

Phase 1

Ecopipam tablet

Food-effect

Phase 1

Clinical Trials (1)

NCT06669091Food-effect Study of Ecopipam Pharmacokinetics

Phase 1

ecopipam HCL

Drug Interaction

Phase 1

Clinical Trials (1)

NCT04902105Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

Phase 1

Ecopipam

Pathological Gambling

Phase 2

Clinical Trials (1)

NCT01215357Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

Phase 2

Ecopipam

Tourette Syndrome in Children

Phase 2

Clinical Trials (1)

NCT04114539Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

Phase 2

Ecopipam

Tourette Syndrome

Phase 2

Clinical Trials (1)

NCT04007991Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

Phase 2

Ecopipam

Tourette's Syndrome

Phase 2

Clinical Trials (1)

NCT02102698Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

Phase 2

Ecopipam

Childhood-Onset Fluency Disorder (Stuttering)

Phase 2

Clinical Trials (1)

NCT04492956Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

Phase 2

Ecopipam

Tourette Syndrome

Phase 3

Clinical Trials (1)

NCT06021522A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Phase 3

Ecopipam

Lesch-Nyhan Disease

Phase 3

Clinical Trials (1)

NCT01751802Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

Phase 3

Ecopipam Hydrochloride

Tourette Disorder

Phase 3

Clinical Trials (1)

NCT05615220Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 17 clinical trials

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo